RYTM Stock Analysis: Buy, Sell, or Hold?
RYTM - Rhythm Pharmaceuticals, Inc. Common Stock
$99.25
-6.49 (-6.14%)
▼
5d:
-2.79%
30d:
-10.11%
90d:
+21.99%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 04, 2026
TODAY
Get Alerted When RYTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RYTM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RYTM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RYTM is currently trading at $99.25, which is considered fair relative to its 30-day fair value range of $104.57 to $112.09.
Technical Outlook: Technically, RYTM is in a strong uptrend. The price is currently testing key support at $98.44. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $138.80 (+39.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RYTM is in a strong uptrend. The price is currently testing key support at $98.44. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $138.80 (+39.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$104.57 -
$112.09
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.1%)
- BULLISH: Trading 39.8% below Wall St target ($138.80)
Trading Range Analysis
30-Day Trading Range
$104.57 -
$112.09
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$98.44
Resistance Level
$110.99
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-151.62
Wall Street Target
$138.80
(+39.8%)
Revenue Growth (YoY)
83.8%
Profit Margin
-93.3%
Share & Embed Analysis
Last updated: August 02, 2026 11:19 PM ET
Data refreshes hourly during market hours. Next update: 12:19 AM
Data refreshes hourly during market hours. Next update: 12:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RYTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Paul German
SELL
5614 shares
2026-03-04
Hunter C Smith
SELL
4385 shares
2026-02-19
Hunter C Smith
SELL
3569 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced RYTM Option Strategies
Professional options setups generated by AI based on today's RYTM price and gamma walls.
